Cancer researchHumansImmune Checkpoint InhibitorsEpigenesisGeneticProtein Serine-Threonine Kinases
Precision Epigenetic Reprogramming: CoREST Inhibition Sensitizes STK11-Mutant Tumors to Immune Checkpoint Blockade Therapy.
De-Chen Lin, Keyue Shen
Published: 202510.1158/0008-5472.CAN-25-4003
Abstract
Loss-of-function mutations in STK11 (also known as LKB1) define a molecular subtype of non-small cell lung cancer that is resistant to immune checkpoint blockade therapy, partially owing to impaired T-cell infiltration and suppressed antigen presenta…
Preview only. Read the full abstract at the source